Table 1.

Main clinical features of the female systemic sclerosis patients included in the study. Data are referred to the total of analysed individuals

Clinical feature	Spain	USA	Germany	The Netherlands	UK
lcSSc	0.70	0.66	0.63	0.71	0.76
dcSSc	0.30	0.34	0.37	0.29	0.24
ACA positive	0.47	0.33	0.40	0.27	0.41
ACA negative	0.49	0.66	0.56	0.71	0.57
ATA positive	0.22	0.18	0.28	0.24	0.15
ATA negative	0.72	0.81	0.68	0.74	0.82
PF positive*	0.22	0.09	0.26	0.36	0.19
PF negative*	0.70	0.37	0.60	0.49	0.18
SSc patients without PF data*	0.08	0.54	0.14	0.15	0.63

ACA, anticentromere antibody; ATA, antitopoisomerase antibody; dcSSc, diffuse cutaneous SSc; lcSSc, limited cutaneous SSc; PF, pulmonary fibrosis; SSc, systemic sclerosis.

^*Pulmonary fibrosis data were obtained by high resolution CT (HRCT) in the European cohorts and by pulmonary function test (FVC<70%) in the US cohort.